Semiquantitative evaluation revealed that the elevated expression of pAKT1, MTOR, pEIF4EBP1 and SLC2A1 in cancer was evident in 47 (94%), 30 (60%), 43 (86%) and 42 (84%) cases, respectively (Fig 6B). Here, SLC2A1 is linked to cancer.